DYN 101
/ Ionis, Dynacure
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
July 12, 2022
DyNaMic: Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Dynacure | Trial completion date: Jun 2023 ➔ Nov 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Mar 2023 ➔ Sep 2025
Trial completion date • Trial primary completion date • Trial withdrawal • Myositis
July 12, 2022
Unite-CNM: Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2 | N=16 | Terminated | Sponsor: Dynacure | Trial completion date: Dec 2022 ➔ Jun 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Jun 2022; Based on tolerability findings at the low dose level thus far, continuation of dosing or even dose escalation is not possible.
Trial completion date • Trial primary completion date • Trial termination • Myositis
August 30, 2021
Unite-CNM: Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2; N=18; Recruiting; Sponsor: Dynacure; Trial completion date: Apr 2022 ➔ Dec 2022; Trial primary completion date: Apr 2022 ➔ Dec 2022
Clinical • Trial completion date • Trial primary completion date • Myositis
February 08, 2021
DyNaMic: Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2; N=9; Not yet recruiting; Sponsor: Dynacure
Clinical • New P1/2 trial • Myositis
May 05, 2020
Unite-CNM: Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2; N=18; Recruiting; Sponsor: Dynacure SAS; Trial completion date: Apr 2021 ➔ Apr 2022; Trial primary completion date: Apr 2021 ➔ Apr 2022
Clinical • Trial completion date • Trial primary completion date
January 21, 2020
Unite-CNM: Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2; N=18; Recruiting; Sponsor: Dynacure SAS; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
July 25, 2019
Unite-CNM: Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
(clinicaltrials.gov)
- P1/2; N=18; Not yet recruiting; Sponsor: Dynacure SAS
Clinical • New P1/2 trial
July 18, 2019
An early phase human drug trial (called phase 1/2) to investigate DYN101 in patients ≥ 16 years of age with a rare muscle disease group called the centronuclear myopathies caused by genetic changes in DNM2 or MTM1 for the drug’s safety, tolerability, how the body processes the drug as well as interactions of the drug with the body and preliminary effects of the drug.
(clinicaltrialsregister.eu)
- P1/2; N=18; Sponsor: Dynacure SAS
Clinical • New P1/2 trial
1 to 8
Of
8
Go to page
1